
Dementia and Alzheimer Disease
Latest News
Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.

A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.

In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.

A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.

Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

Here's some of what is coming soon to NeurologyLive® this week.

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Fast track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.




























